China’s National Medical Products Administration (NMPA) issued Announcement No. 24 on June 30, 2026, establishing the first formal regulatory framework for Brain-Computer Interface (BCI) medical devices. The new guidelines categorize devices based on invasiveness, clinical purpose, and the presence of artificial intelligence, providing a definitive rulebook for developers and investors to determine regulatory scrutiny and market access pathways.
How does the NMPA classify BCI medical devices?
The NMPA sorts BCI technology into risk-based classes to determine the level of clinical evidence required for market entry. According to the June 2026 guidelines, most BCI products fall under Class III, the highest regulatory tier. This includes all implantable devices, non-invasive treatment devices, and non-invasive functional compensation or rehabilitation systems that utilize AI.
The only exception currently available is for non-invasive, non-AI stroke rehabilitation devices, which are classified as Class II. This distinction exists because stroke rehabilitation protocols are considered mature, and the absence of AI algorithms reduces the risk of “dynamic uncertainty” or misinterpretation of patient intent that could lead to physical injury, as noted by the NMPA.
Why is the integration of AI a regulatory trigger?
The presence of artificial intelligence shifts the regulatory burden for BCI devices. The NMPA explicitly states that if a device uses an AI algorithm for real-time decoding, it must be classified as Class III. This is because the agency evaluates safety and efficacy at the full system level rather than the algorithm in isolation.
Consequently, standalone EEG-analysis software that does not perform real-time feedback is excluded from these specific medical device guidelines. Companies developing AI-driven components should treat this classification as a core technology consideration, not a late-stage formality, according to the NMPA’s 2026 framework.
What are the boundaries of BCI medical regulation?
Not all BCI products are subject to medical device oversight. The NMPA guideline defines a regulated BCI device as an active system that measures and decodes central nervous system signals in real time to enable bidirectional interaction. Devices falling outside this scope include:
- Systems reading only peripheral nerve, muscle (EMG), or cardiac (ECG) signals.
- Devices that only collect signals or provide one-way stimulation without real-time feedback.
- Consumer products intended for gaming, VR/AR, or general cognitive enhancement.
Manufacturers of non-medical BCI products must explicitly state their devices are not for therapeutic use. The NMPA prohibits these firms from making claims—even implicitly—that their products can improve, restore, or replace central nervous system function.
What should foreign investors consider for market entry?
Predictability is the primary benefit of the new NMPA framework. Previously, companies faced case-by-case regulatory judgments; now, foreign entrants can map their product concepts to specific review pathways before committing capital.
However, the competitive landscape is shifting. Provinces such as Sichuan, Hubei, and Zhejiang are already setting medical service pricing for BCI treatments. Because domestic competitors are backed by state industrial policies—which target globally competitive Chinese BCI enterprises by 2030—foreign firms may find that joint ventures or licensing structures offer a more efficient path to generating the local evidence required for Class III submissions.
Frequently Asked Questions
Can foreign companies enter the China BCI market?
Yes. BCI is not currently a restricted sector for foreign investment. However, firms must comply with the NMPA’s classification guidelines to access the national insurance reimbursement system, which is a major driver of patient volume.
What if a product does not fit the provided categories?
The NMPA acknowledges that technology in this field is evolving. Companies with novel BCI products can utilize the NMPA’s classification determination procedure to receive guidance on their specific regulatory pathway rather than waiting for future guideline revisions.
Are consumer BCI headsets regulated as medical devices?
No, provided they are not marketed for therapeutic use. If a company claims their non-medical device can restore or improve central nervous system function, it will be subject to medical device regulation.
For further assistance with regulatory strategy and market entry in China, explore our business support services or contact our team to discuss your product roadmap.
